{"id":32869,"date":"2025-07-30T08:47:22","date_gmt":"2025-07-30T08:47:22","guid":{"rendered":"https:\/\/ibima.eu\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/"},"modified":"2025-07-30T08:47:22","modified_gmt":"2025-07-30T08:47:22","slug":"estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/","title":{"rendered":"Estudio multic\u00e9ntrico controlado, aleatorizado y abierto sobre la eficacia del tratamiento intratumoral neoadyuvante con Daromun (L19IL2 + L19TNF) seguido de cirug\u00eda y una terapia adyuvante frente a cirug\u00eda y una terapia adyuvante en pacientes con melanoma en estadio IIIB\/C"},"content":{"rendered":"

ELISABETH PEREZ RUIZ – ENSAYO CLINICO CON MEDICAMENTOS – III – PHILOGEN S.P.A<\/p>\n","protected":false},"excerpt":{"rendered":"

ELISABETH PEREZ RUIZ – ENSAYO CLINICO CON MEDICAMENTOS – III – PHILOGEN S.P.A<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2296],"tags":[],"class_list":["post-32869","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-b-05-ensayos-clinicos"],"acf":[],"yoast_head":"\nEstudio multic\u00e9ntrico controlado, aleatorizado y abierto sobre la eficacia del tratamiento intratumoral neoadyuvante con Daromun (L19IL2 + L19TNF) seguido de cirug\u00eda y una terapia adyuvante frente a cirug\u00eda y una terapia adyuvante en pacientes con melanoma en estadio IIIB\/C - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estudio multic\u00e9ntrico controlado, aleatorizado y abierto sobre la eficacia del tratamiento intratumoral neoadyuvante con Daromun (L19IL2 + L19TNF) seguido de cirug\u00eda y una terapia adyuvante frente a cirug\u00eda y una terapia adyuvante en pacientes con melanoma en estadio IIIB\/C - Ibima\" \/>\n<meta property=\"og:description\" content=\"ELISABETH PEREZ RUIZ – ENSAYO CLINICO CON MEDICAMENTOS – III – PHILOGEN S.P.A\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:47:22+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"Estudio multic\u00e9ntrico controlado, aleatorizado y abierto sobre la eficacia del tratamiento intratumoral neoadyuvante con Daromun (L19IL2 + L19TNF) seguido de cirug\u00eda y una terapia adyuvante frente a cirug\u00eda y una terapia adyuvante en pacientes con melanoma en estadio IIIB\\\/C\",\"datePublished\":\"2025-07-30T08:47:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\\\/\"},\"wordCount\":59,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - B-05\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\\\/\",\"name\":\"Estudio multic\u00e9ntrico controlado, aleatorizado y abierto sobre la eficacia del tratamiento intratumoral neoadyuvante con Daromun (L19IL2 + L19TNF) seguido de cirug\u00eda y una terapia adyuvante frente a cirug\u00eda y una terapia adyuvante en pacientes con melanoma en estadio IIIB\\\/C - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:47:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estudio multic\u00e9ntrico controlado, aleatorizado y abierto sobre la eficacia del tratamiento intratumoral neoadyuvante con Daromun (L19IL2 + L19TNF) seguido de cirug\u00eda y una terapia adyuvante frente a cirug\u00eda y una terapia adyuvante en pacientes con melanoma en estadio IIIB\\\/C\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estudio multic\u00e9ntrico controlado, aleatorizado y abierto sobre la eficacia del tratamiento intratumoral neoadyuvante con Daromun (L19IL2 + L19TNF) seguido de cirug\u00eda y una terapia adyuvante frente a cirug\u00eda y una terapia adyuvante en pacientes con melanoma en estadio IIIB\/C - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/","og_locale":"es_ES","og_type":"article","og_title":"Estudio multic\u00e9ntrico controlado, aleatorizado y abierto sobre la eficacia del tratamiento intratumoral neoadyuvante con Daromun (L19IL2 + L19TNF) seguido de cirug\u00eda y una terapia adyuvante frente a cirug\u00eda y una terapia adyuvante en pacientes con melanoma en estadio IIIB\/C - Ibima","og_description":"ELISABETH PEREZ RUIZ – ENSAYO CLINICO CON MEDICAMENTOS – III – PHILOGEN S.P.A","og_url":"https:\/\/ibima.eu\/es\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:47:22+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"Estudio multic\u00e9ntrico controlado, aleatorizado y abierto sobre la eficacia del tratamiento intratumoral neoadyuvante con Daromun (L19IL2 + L19TNF) seguido de cirug\u00eda y una terapia adyuvante frente a cirug\u00eda y una terapia adyuvante en pacientes con melanoma en estadio IIIB\/C","datePublished":"2025-07-30T08:47:22+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/"},"wordCount":59,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - B-05"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/","url":"https:\/\/ibima.eu\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/","name":"Estudio multic\u00e9ntrico controlado, aleatorizado y abierto sobre la eficacia del tratamiento intratumoral neoadyuvante con Daromun (L19IL2 + L19TNF) seguido de cirug\u00eda y una terapia adyuvante frente a cirug\u00eda y una terapia adyuvante en pacientes con melanoma en estadio IIIB\/C - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:47:22+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Estudio multic\u00e9ntrico controlado, aleatorizado y abierto sobre la eficacia del tratamiento intratumoral neoadyuvante con Daromun (L19IL2 + L19TNF) seguido de cirug\u00eda y una terapia adyuvante frente a cirug\u00eda y una terapia adyuvante en pacientes con melanoma en estadio IIIB\/C"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/es\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=32869"}],"version-history":[{"count":3,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32869\/revisions"}],"predecessor-version":[{"id":55956,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32869\/revisions\/55956"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=32869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/categories?post=32869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/tags?post=32869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}